Arrowhead launches Ablaris Therapeutics; Abbott, EpiTherapeutics in cancer-drug deal;

@FierceBiotech: InterMune's shares rise as CHMP backs pirfenidone. Report | Follow @FierceBiotech

 @JohnCFierce: Wonder what big pharma thinks about China's thoughts on slashing drug prices unilaterally. Emerging market or mayhem? Report | Follow @JohnCFierce

> Following a licensing deal with MD Anderson Cancer Center to obtain technology for weight loss and obesity-related metabolic conditions, Arrowhead Research Corporation says it has launched a new company, Ablaris Therapeutics, commercialize the platform. Ablaris release

> After disappointing results, Eli Lilly has suspended its late-stage melanoma trial. Tasisulam may be tested for other cancers, but will not be considered for melanoma after concerns arose from the trial data, triggering a clinical hold. Story

> Abbott Labs and EpiTherapeutics have entered a three-year deal to create cancer drugs using small-molecule inhibitors. Abbott release

> Bristol-Myers Squibb will manufacture, develop and commercialize an HIV treatment. Festinavir, a nucleoside reverse transcriptase inhibitor, is in Phase II development; the deal gives Oncolys BioPharma up to $286 million for festinavir. BMS release

And Finally... A woman who is incapable of feeling fear may help scientists discover treatments for post-traumatic stress disorder. Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.